Nicht aus der Schweiz? Besuchen Sie lehmanns.de
RNA Delivery Function for Anticancer Therapeutics - Loutfy H. Madkour

RNA Delivery Function for Anticancer Therapeutics

Buch | Hardcover
424 Seiten
2022
Taylor & Francis Ltd (Verlag)
978-1-032-13516-8 (ISBN)
CHF 319,95 inkl. MwSt
  • Versand in 10-20 Tagen
  • Versandkostenfrei
  • Auch auf Rechnung
  • Artikel merken
This book presents an overview of the current status of translating the RNAi cancer therapeutics in the clinic, a brief description of the biological barriers in drug delivery, and the roles of imaging in aspects of administration route, systemic circulation, and cellular barriers for the clinical translation of RNAi cancer therapeutics, and with partial content for discussing the safety concerns.

It then focuses on imaging-guided delivery of RNAi therapeutics in preclinical development, including the basic principles of different imaging modalities, and their advantages and limitations for biological imaging. With growing number of RNAi therapeutics entering the clinic, various imaging methods will play an important role in facilitating the translation of RNAi cancer therapeutics from bench to bedside. RNAi technique has become a powerful tool for basic research to selectively knock down gene expression in vitro and in vivo. Our scientific and industrial communities have started to develop RNAi therapeutics as the next class of drugs for treating a variety of genetic disorders, such as cancer and other diseases that are particularly hard to address with current treatment strategies.

Key Features:
  • Provides insight into the current advances and hurdles of RNAi therapeutics.
  • Accelerates RNAi, miRNAs, and siRNA drug development for cancer therapy from bench to bedside.
  • Addresses various modifications and novel delivery strategies for miRNAs, piRNAs and siRNA delivery in anticancer therapeutics.
  • Explores the need for the interaction of hematologists,cell biologists, immunologists, and material scientists in the development of novel cancer therapies.
  • Describes the current status of clinical trials related to miRNA and siRNA-based cancer therapy
  • Presents remaining issues that need to be overcome to establish successful therapies.

Prof. Loutfy H. Madkour is a professor of physical chemistry and nanoscience at Tanta University (Egypt). He received his BSc, MSc, and PhD in physical chemistry from the Cairo, Minia, and Tanta universities in Egypt, respectively. He has published 200 peer-reviewed original research articles, 20 review articles, and 8 books. He is an editorial board member of several international journals, including International Journal of Industrial Chemistry (IJIC-Springer), International Journal of Ground Sediment & Water, Global Drugs and Therapeutics, Chronicles of Pharmaceutical Science, Journal of Targeted Drug Delivery, UPI Journal of Pharmaceutical, Medical and Health Sciences, Global Journal of Nanomedicine, Clinical Pharmacology and Toxicology Research, Journal of Pharmacology & Pharmaceutical Research, LOJ Pharmacology & Clinical Research, CPQ Medicine, Pharmaceutical Sciences & Analytical Research Journal, Japan Journal of Research, Organic & Medicinal Chemistry International Journal, Nanotechnology & Applications, Materials Science Journal, Journal of Chemical Science and Chemical Engineering (Journals of- JCSCE), United Journal of Nanotechnology and Medicine, Clinical Practice (Therapy) journal, Journal of Materials New Horizons, Journal of Radiology and Medical Imaging. MedDocs Publishers, World Journal of Pharmacy and Pharmaceutical Sciences WJPPS and Journal of Material Science and Technology Research - RBM.

Chapter 01


Cancer epigenetic mechanisms-DNA methylomes, histone codes and miRNAs


Chapter 02


Circulating miRNAs cancer biomarkers and epigenetic modifications in human cancer


Chapter 03


The role of circulating microRNAs in diagnosis, prognosis and treatment targets of cancer and diseases


Chapter 04


MicroRNAs potential in human cancer as therapeutic targets and novel biomarkers


Chapter 05


Biological function of miRNAs and piRNAs targets in cancer tissues


Chapter 06


Delivery strategies for siRNA and modifications process of RNAi therapeutics for cancer treatment


Chapter 07


Clinical small interfering siRNA-based conjugate systems for RNAi cancer cells therapy


Chapter 08


Potential targeted for siRNA in types of genetic diseases cancer therapeutics


Chapter 09


Recent advanced of microRNA molecules delivery as anticancer drugs


Chapter 10


DNA damaging cancer therapies and FDA novel drug approvals


Chapter 11


Therapeutic potential role of miRNAs in pancreatic and prostate cancer cells


Chapter 12


Regulation of microRNAs and their role in regeneration and cancer diseases


Chapter 13


Novel classes of non-coding RNAs (ncRNAs) and cancer biology therapeutic targets


Chapter 14


Advances in the inhibition and optimization of checkpoint kinases by small molecules for the treatment of cancer


Chapter 15


Recent therapeutic prospects of microRNAs and siRNA delivery systems in cancer treatment nano-biotechnology

Erscheinungsdatum
Reihe/Serie Nanotechnology for Drugs, Vaccines and Smart Delivery Systems
Zusatzinfo 56 Line drawings, color; 35 Line drawings, black and white; 24 Halftones, color; 1 Halftones, black and white; 33 Tables, black and white; 80 Illustrations, color; 36 Illustrations, black and white
Verlagsort London
Sprache englisch
Maße 210 x 280 mm
Gewicht 943 g
Einbandart gebunden
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete Biomedizin
Medizin / Pharmazie Medizinische Fachgebiete Onkologie
Medizin / Pharmazie Medizinische Fachgebiete Pharmakologie / Pharmakotherapie
Medizin / Pharmazie Pharmazie
Medizin / Pharmazie Physiotherapie / Ergotherapie Orthopädie
Naturwissenschaften Biologie
Naturwissenschaften Chemie Physikalische Chemie
Technik Maschinenbau
Technik Medizintechnik
Technik Umwelttechnik / Biotechnologie
Schlagworte Arzneimittelabgabe • Cancer drug delivery • Delivery of siRNA • DNA- u. RNA-Therapien • miRNA • Neuartige Arzneimittelabgabe • RNA-based therapeutics • RNA Impfstoff • RNA interference (RNAi) • RNA-Interferenz-Technologie • RNAi Therapeutics • siRNA
ISBN-10 1-032-13516-6 / 1032135166
ISBN-13 978-1-032-13516-8 / 9781032135168
Zustand Neuware
Informationen gemäß Produktsicherheitsverordnung (GPSR)
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich
Entstehung, Progression und Therapie von Krebs

von Christoph Wagener; Oliver Müller

Buch (2022)
Thieme (Verlag)
CHF 279,95
Finding Meaning in a Genome

von Danny E. Miller; Angela L. Miller; R. Scott Hawley

Buch | Softcover (2023)
John Wiley & Sons Inc (Verlag)
CHF 128,65